MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain
Portfolio Pulse from Benzinga Newsdesk
MyMD Pharmaceuticals announced preclinical study results showing that its novel cannabidiol analog, Supera-CBD, reduced acute inflammatory pain. The drug provided long-lasting pain relief lasting up to five hours. The company was also issued Japanese Patent No. 7293561 B2, covering Supera-CBD as a new molecular entity, in pharmaceutical formulations, and for use in therapeutic treatments.
October 19, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MyMD Pharmaceuticals' Supera-CBD shows promising results in preclinical studies, potentially boosting the company's prospects. The issuance of a Japanese patent further strengthens the company's position.
The positive preclinical results for Supera-CBD suggest that the drug could be a significant product for MyMD Pharmaceuticals. The issuance of a Japanese patent further protects the company's intellectual property, potentially leading to increased investor confidence and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100